Preclinical and clinical studies of breast cancer prevention with transdermal anti-progesterone agents

Project: Research project

Project Details


In the coming year, we propose to test the efficacy of combination therapy of SPRM (ulipristal acetate) and selective COX-2 inhibitor (Celecoxib) for prevention of Brca1 deficient mammary tumorigenesis in a mouse model.
Effective start/end date10/1/209/30/22


  • Breast Cancer Research Foundation (BCRF-20-087)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.